Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Segurança e eficácia do MK-1200 em participantes com tumores sólidos avançados

11 de maio de 2026 atualizado por: Merck Sharp & Dohme LLC

Um estudo aberto de fase 1/2 para avaliar a segurança e eficácia do MK-1200 em participantes com tumores sólidos avançados

O objetivo do estudo é avaliar a eficácia e segurança da monoterapia com MK-1200 em participantes com câncer avançado/metastático da junção gástrica/gastroesofágica (GEJ), câncer de esôfago, câncer do trato biliar e adenocarcinoma ductal pancreático que receberam ou foram intolerantes a todos os tratamentos conhecidos por conferir benefício clínico. A Parte 1 do estudo será um escalonamento de dose para determinar a dose máxima tolerada (MTD). A Parte 2 avaliará a segurança e eficácia do MK-1200 em 2 doses diferentes

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

13

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Austrália
    • Victoria
      • Melbourne, Victoria, Austrália, 3004
        • The Alfred Hospital ( Site 0103)
  • Chile
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chile, 8420383
        • Bradfordhill-Clinical Area ( Site 0301)
  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100142
        • Beijing Cancer hospital-Digestive Oncology ( Site 0401)
    • Fujian
      • Fuzhou, Fujian, China, 350000
        • Fujian Cancer Hospital-oncology department ( Site 0409)
    • Jiangsu
      • Huai'an, Jiangsu, China, 223300
        • First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0415)
  • Coréia do Sul
      • Seoul, Coréia do Sul, 06351
        • Samsung Medical Center-Division of Hematology/Oncology ( Site 1003)
  • Estados Unidos
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40202
        • The University of Louisville, James Graham Brown Cancer Center ( Site 0004)
    • Michigan
      • Grand Rapids, Michigan, Estados Unidos, 49546
        • START Midwest ( Site 0014)
    • Texas
      • San Antonio, Texas, Estados Unidos, 78229
        • South Texas Accelerated Research Therapeutics (START) ( Site 0005)
    • Utah
      • West Valley City, Utah, Estados Unidos, 84119
        • START Mountain Region ( Site 0015)
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • University of Virginia Health System-Hematology-Oncology ( Site 0009)
  • Israel
      • Haifa, Israel, 3109601
        • Rambam Health Care Campus-Oncology Division ( Site 0602)
      • Jerusalem, Israel, 9112001
        • Hadassah Medical Center ( Site 0604)
      • Petah Tikva, Israel, 4941492
        • Rabin Medical Center-Oncology ( Site 0603)
      • Ramat Gan, Israel, 5265601
        • Sheba Medical Center ( Site 0605)
      • Tel Aviv, Israel, 6423906
        • Sourasky Medical Center ( Site 0601)

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Critério de inclusão:

  • Tumor sólido avançado (irressecável e/ou metastático) confirmado: câncer gástrico (incluindo câncer da junção gastroesofágica), câncer de esôfago, câncer do trato biliar ou adenocarcinoma ductal pancreático
  • Os participantes que sofreram Eventos Adversos (EAs) devido a terapias anticancerígenas anteriores devem ter se recuperado para < Grau 1 ou valor basal
  • Os participantes infectados pelo vírus da imunodeficiência humana (HIV) devem ter o HIV bem controlado em terapia antirretroviral
  • Os participantes positivos para o antígeno de superfície da hepatite B (HBsAg) são elegíveis se tiverem recebido terapia antiviral para o vírus da hepatite B (HBV) por pelo menos 4 semanas e tiverem carga viral de HBV indetectável
  • Participantes com histórico de infecção pelo vírus da hepatite C (HCV) são elegíveis se a carga viral do HCV for indetectável
  • Recebeu e progrediu em ou após 1 ou 2 linhas de terapia anteriores

Critério de exclusão:

  • Doença digestiva grave ativa
  • História das principais doenças cardiovasculares
  • História de infarto agudo do miocárdio; angina instável; acidente vascular cerebral ou ataque isquêmico transitório nos 6 meses anteriores à primeira dose da intervenção do estudo
  • Uso de marca-passo cardíaco
  • Diabetes ou hipertensão que não pode ser controlada com medicamentos
  • Participantes infectados pelo HIV com histórico de sarcoma de Kaposi e/ou doença multicêntrica de Castleman
  • Recebeu terapia anticâncer sistêmica anterior, incluindo agentes em investigação, dentro de 4 semanas antes da intervenção do estudo
  • Recebeu radioterapia prévia dentro de 2 semanas do início da intervenção do estudo ou apresenta toxicidade relacionada à radiação, necessitando de corticosteróides
  • Malignidade adicional conhecida que está progredindo ou que necessitou de tratamento ativo nos últimos 2 anos
  • Metástases ativas conhecidas no sistema nervoso central (SNC) e/ou meningite carcinomatosa
  • Infecção ativa que requer terapia sistêmica
  • Não se recuperaram adequadamente de uma grande cirurgia ou apresentam complicações cirúrgicas contínuas

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Parte 1: MK-1200
Na Parte 1, os participantes receberão doses crescentes de MK-1200 por meio de infusão intravenosa (IV) a cada 2 semanas (Q2W) até que qualquer critério de descontinuação seja atendido.
Biológico: MK-1200
Infusão intravenosa
Medicamento: Antiemético
Um ou mais antieméticos profiláticos (por ex. Antagonistas do receptor 5-HT3, dexametasona, antagonistas do receptor da neuroquinina-1, etc.) podem ser selecionados com base na resposta anterior dos participantes a medicamentos antieméticos e fatores individuais, e serão administrados de acordo com o rótulo do produto aprovado antes da infusão de MK-1200
Experimental: Part 2: MK-1200 Cohort A
In Part 2, participants in Cohort A will receive either Dose 1 or Dose 2 of MK-1200 (determined from Part 1) via IV infusion Q2W until any discontinuation criteria are met.
Biológico: MK-1200
Infusão intravenosa
Medicamento: Antiemético
Um ou mais antieméticos profiláticos (por ex. Antagonistas do receptor 5-HT3, dexametasona, antagonistas do receptor da neuroquinina-1, etc.) podem ser selecionados com base na resposta anterior dos participantes a medicamentos antieméticos e fatores individuais, e serão administrados de acordo com o rótulo do produto aprovado antes da infusão de MK-1200
Experimental: Part 2: MK-1200 Cohort B
In Part 2, participants in Cohort B will receive Dose 1 of MK-1200 (determined from Part 1) via IV infusion Q2W until any discontinuation criteria are met.
Biológico: MK-1200
Infusão intravenosa
Medicamento: Antiemético
Um ou mais antieméticos profiláticos (por ex. Antagonistas do receptor 5-HT3, dexametasona, antagonistas do receptor da neuroquinina-1, etc.) podem ser selecionados com base na resposta anterior dos participantes a medicamentos antieméticos e fatores individuais, e serão administrados de acordo com o rótulo do produto aprovado antes da infusão de MK-1200

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Part 1
Prazo: During the first two 14-day cycles (Up to approximately 28 days)

The occurrence of any of the following toxicities within 28 days after the first dose of study intervention were considered a DLT, if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration:

  • Grade 4 nonhematologic toxicity (not laboratory). Any nonhematologic AE ≥Grade 3 in severity was considered a DLT, with pre-specified exceptions
  • Any Grade 3 or Grade 4 laboratory value (hematologic or nonhematologic), with pre-specified exceptions
  • Febrile neutropenia Grade 3 or Grade 4 as prespecified by the protocol
  • Prolonged delay (>2 weeks) in initiating Cycle 2 due to intervention-related toxicity
  • Any intervention-related toxicity that caused the participant to discontinue intervention during Cycle 1
  • Missed >25% of MK-1200 doses as a result of drug-related AEs during the first cycle
  • Grade 5 toxicity
During the first two 14-day cycles (Up to approximately 28 days)
Number of Participants Who Experience One or More Adverse Events (AEs) - Part 1 & Part 2
Prazo: Up to approximately 12 months
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an AE is reported for each arm.
Up to approximately 12 months
Number of Participants Who Discontinue Study Intervention Due to an AE - Part 1 & Part 2
Prazo: Up to approximately 9 months
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study intervention due to an AE is reported for each arm.
Up to approximately 9 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) - Part 2 Cohort A
Prazo: Up to approximately 13 months
ORR was defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by blinded independent central review (BICR). As pre-specified by the protocol, this analysis was to only include all participants randomized to Part 2 Cohort A who received at least 1 dose of study intervention.
Up to approximately 13 months
ORR Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B
Prazo: Up to approximately 13 months
ORR was defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator.
Up to approximately 13 months
Area Under the Concentration Versus Time Curve From Time 0 to 336 Hours (AUC0-336) of MK-1200-Antibody-Drug Conjugate (ADC) - Parts 1 and 2
Prazo: Cycle 1 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
AUC0-336 was defined as the area under the concentration versus time curve of MK-1200-ADC from time 0 to 336 Hours. Blood samples were collected at pre-specified timepoints to determine the AUC0-336 of the MK-1200-ADC.
Cycle 1 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
AUC0-336 of the Conjugated Toxin Payload (KL610023) - Parts 1 and 2
Prazo: Cycle 1 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
AUC0-336 was defined as the area under the concentration versus time curve of KL610023 from time 0 to 336 Hours. Blood samples were collected at pre-specified timepoints to determine AUC0-336 of KL610023.
Cycle 1 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Period (AUC0-tau) of MK-1200-ADC - Parts 1 and 2
Prazo: Cycle 4 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
AUC0-tau was defined as the area under the concentration versus time curve of MK-1200-ADC from time 0 to the end of the 14-day dosing period (Cycle 4, 336 hours post-dose). Blood samples were collected at pre-specified timepoints to determine AUC0-tau of the MK-1200-ADC.
Cycle 4 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
AUC0-tau of KL610023 - Parts 1 and 2
Prazo: Cycle 4 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
AUC0-tau is defined as the area under the concentration versus time curve of KL610023 from time 0 to the end of the 14-day dosing period (Cycle 4, 336 hours post-dose). Blood samples were collected at pre-specified timepoints to determine AUC0-tau of KL610023.
Cycle 4 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Minimum Concentration (Cmin) of MK-1200-ADC - Part 1 & Part 2
Prazo: Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Cmin was defined as the minimum concentration of MK-1200-ADC observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples were collected at pre-specified timepoints to determine Cmin of the MK-1200-ADC.
Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Cmin of KL610023 - Part 1 & Part 2
Prazo: Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Cmin was defined as the minimum concentration of KL610023 observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples were collected at pre-specified timepoints to determine Cmin of KL610023.
Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Maximum Concentration (Cmax) of MK-1200-ADC - Part 1 & Part 2
Prazo: Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Cmax was defined as the maximum or 'peak' concentration of MK-1200-ADC observed after its administration. Blood samples were collected at pre-specified timepoints to determine Cmax of the MK-1200-ADC.
Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Cmax of KL610023 - Part 1 & Part 2
Prazo: Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Cmax was defined as the maximum or 'peak' concentration of KL610023 observed after its administration. Blood samples were collected at pre-specified timepoints to determine Cmax of KL610023.
Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR - Part 2 Cohort A
Prazo: Up to approximately 13 months
For participants demonstrating a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from the first documented evidence of a CR or a PR until Progressive Disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. As pre-specified by the protocol, DOR for Part 2 Cohort A was planned to be assessed by BICR and was to include all participants randomized to Part 2 Cohort A who received at least one dose of study intervention.
Up to approximately 13 months
DOR Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B
Prazo: Up to approximately 13 months
For participants demonstrating a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from the first documented evidence of a CR or a PR until PD or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by the investigator is reported.
Up to approximately 13 months
Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR - Part 2 Cohort A
Prazo: Up to approximately 13 months
PFS was defined as the time from randomization to the first documented PD by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. As pre-specified by the protocol, PFS for Part 2 Cohort A was planned to be assessed by BICR and was to only include all participants randomized to Part 2 Cohort A who received at least one dose of study intervention.
Up to approximately 13 months
PFS Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B
Prazo: Up to approximately 13 months
PFS was defined as the time from randomization to the first documented PD by investigator or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by the investigator is reported.
Up to approximately 13 months
Overall Survival (OS) - Part 1 & Part 2
Prazo: Up to approximately 13 months
OS was defined as the time from randomization to death due to any cause.
Up to approximately 13 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Merck Sharp & Dohme LLC

Investigadores

  • Diretor de estudo: Medical Director, Merck Sharp & Dohme LLC

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Links úteis

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

28 de fevereiro de 2024

Conclusão Primária (Real)

17 de junho de 2025

Conclusão do estudo (Real)

17 de junho de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

26 de janeiro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de janeiro de 2024

Primeira postagem (Real)

5 de fevereiro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de maio de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 1200-002
  • U1111-1298-7820 (Identificador de registro: UTN)
  • MK-1200-002 (Outro identificador: MSD)
  • 2023-508684-68-00 (Identificador de registro: EU CT)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever